XML 72 R60.htm IDEA: XBRL DOCUMENT v3.19.2
FINANCIAL INSTRUMENTS (Details 3)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
customer
Dec. 31, 2017
customer
Dec. 31, 2018
USD ($)
Credit Risk          
Investment in convertible preferred B shares         $ 14,100,000
Additional cash investments in TELA Bio's convertible preferred B shares $ 1,600,000        
Number of major customers | customer     3 3  
Amount of allowance for doubtful accounts 0 $ 0 $ 0   $ 0
Accounts receivable | Credit risk | Major customer one          
Credit Risk          
Concentration risk (as a percent)     31.00% 32.00%  
Accounts receivable | Credit risk | Major customer two          
Credit Risk          
Concentration risk (as a percent)     30.00% 32.00%  
Accounts receivable | Credit risk | Major customer three          
Credit Risk          
Concentration risk (as a percent)     27.00% 29.00%  
Myoscience Acquisition          
Credit Risk          
Acquisition-related contingent consideration $ 28,500,000 28,500,000 $ 28,500,000    
Change in fair value of the contingent consideration since acqusition   $ 0      
Remaining term of the milestone achievement period (in years)   4 years 8 months 12 days